-
1 Comment
Aclaris Therapeutics, Inc is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 87.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 173.9.
Aclaris Therapeutics, Inc's total revenue rose by 44.3% to $2M since the same quarter in the previous year.
Its net income has increased by 29.2% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.1% to $-9M since the same quarter in the previous year.
Based on the above factors, Aclaris Therapeutics, Inc gets an overall score of 5/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US00461U1051 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Exchange | NASDAQ |
| Target Price | 29.13 |
|---|---|
| Beta | 0.61 |
| PE Ratio | None |
| Market Cap | 594M |
| Dividend Yield | 0.0% |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ACRS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
